Patrick Donnelly

David Windley

Matthew Larew

Paul Knight

Curtis Moiles

Douglas Schenkel

Michael Ryskin

Tejas Savant

Avantika Dhabaria

Daniel Leonard

Dan Leonard

Dave Windley

Doug Schenkel

Jacob Johnson

Larry Solow

Lawrence Solow

Mac Etoch

Matt Larew

Pete Lucas

Steven Etoch

Yuko Oku

- Stevanato Group reported strong Q2 2025 performance, with **10%** revenue growth at constant currency and **13%** growth in high-value solutions, contributing to a **200 basis point** expansion in gross profit margin.  **[1849853_2155371_2]** 
- The company is making significant investments in new facilities in **Fishers, Indiana**, and **Latina, Italy**, to expand capacity for high-value products, with Fishers projected to achieve positive gross margin by the end of **2025** and full ramp-up by **2028**.  **[1849853_2155371_1]** **[1849853_2155371_2]** **[1849853_2155371_6]** 
- A strategic shift towards high-value solutions has been a primary driver of profitability, increasing their revenue contribution from **17%** in 2019 to approximately **40%** and expanding the mid-margin level by over **500 basis points**.  **[1849853_2155371_3]** 
- Management anticipates a normalization of vial demand in **2026** with steady low single-digit growth and expects its engineering segment to return to single-digit growth towards **2027** after a temporary decline in 2025.  **[1849853_2155371_3]** **[1849853_2155371_4]** 
- Stevanato Group is well-positioned in the GLP-1 therapies market and benefits from multi-year contracts with anchor customers, which provide visibility and protection for its investments.  **[1849853_2155371_5]** **[1849853_2155371_6]**

Stevanato Group Reports Strong Q2 2025 Performance and Outlines Growth Drivers

Stevanato Group S.p.A. (STVN)